Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study) by Mototsugu Shimokawa, Hiroshi Tanaka, Nobuyuki Yamamoto, Koichi Azuma, Hidetoshi Hayashi, Ryo Toyozawa, Kazumi Nishino, Kazuhiko Nakagawa, Isamu Okamoto, Hideo Saka, Takashi Seto, Kaname Nosaki, Shunichi Sugawara, Haruyasu Murakami, Terufumi Kato, Seiji Niho, Masahide Oki, Hiroshige Yoshioka, Haruko Daga, Rie Tohnai

Get full text

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

Get full text